Galectin Therapeutics Inc. (NASDAQ:GALT) Holdings Raised by Retirement Guys Formula LLC

Retirement Guys Formula LLC grew its position in Galectin Therapeutics Inc. (NASDAQ:GALT) by 143.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 155,343 shares of the company’s stock after acquiring an additional 91,526 shares during the quarter. Retirement Guys Formula LLC owned approximately 0.25% of Galectin Therapeutics worth $200,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Stratos Wealth Partners LTD. boosted its position in Galectin Therapeutics by 27.4% during the 4th quarter. Stratos Wealth Partners LTD. now owns 51,550 shares of the company’s stock valued at $66,000 after purchasing an additional 11,100 shares during the period. Traynor Capital Management Inc. boosted its position in Galectin Therapeutics by 29.9% during the 4th quarter. Traynor Capital Management Inc. now owns 55,670 shares of the company’s stock valued at $72,000 after purchasing an additional 12,799 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Galectin Therapeutics by 46.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 51,369 shares of the company’s stock valued at $66,000 after purchasing an additional 16,271 shares during the period. JPMorgan Chase & Co. boosted its position in Galectin Therapeutics by 161.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company’s stock valued at $84,000 after purchasing an additional 18,907 shares during the period. Finally, Geode Capital Management LLC boosted its position in Galectin Therapeutics by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock valued at $2,372,000 after purchasing an additional 20,817 shares during the period. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Trading Up 0.8 %

Shares of GALT stock opened at $1.31 on Wednesday. Galectin Therapeutics Inc. has a 1 year low of $0.73 and a 1 year high of $4.27. The stock has a fifty day moving average of $1.39 and a two-hundred day moving average of $2.17.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on GALT. StockNews.com lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, December 30th. HC Wainwright restated a “neutral” rating on shares of Galectin Therapeutics in a research report on Friday, December 27th.

Insiders Place Their Bets

In other news, CEO Joel Lewis sold 56,000 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $0.89, for a total value of $49,840.00. Following the completion of the sale, the chief executive officer now owns 897,012 shares in the company, valued at $798,340.68. This represents a 5.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Jack W. Callicutt sold 40,000 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.89, for a total value of $35,600.00. Following the completion of the sale, the chief financial officer now owns 7,614 shares of the company’s stock, valued at approximately $6,776.46. This trade represents a 84.01 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,654 shares of company stock worth $97,456. 50.10% of the stock is owned by company insiders.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.